Eurosarcoidosis inaugurates Scientific Advisory Board
Woerden, Netherlands, 19 February 2024 – Eurosarcoidosis, the European Sarcoidosis Foundation, has appointed a seven-member Scientific Advisory Board. The Board will advise the Foundation on research policies, priorities and opportunities, and become operational from March 2024.
The Scientific Advisory Board consists of:
Chairman
Jan Grutters MD PhD
Pulmonologist, ILD Centre of Excellence, St Antonius Hospital, Nieuwegein, Netherlands
Professor of Insterstitial Lung Diseases, Utrecht University Medical Centre, Utrecht, Netherlands
Secretary (and deputy chairman)
Marcel Veltkamp MD PhD
Pulmonologist, ILD Centre of Excellence, St Antonius Hospital, Nieuwegein, Netherlands
Members
Johan Grunewald PhD
Professor Emeritus of Experimental Pulmonary Medicine, Karolinska University Hospital, Stockholm, Sweden
Dominique Israël-Biet MD PhD
Professor Emeritus of Respiratory Diseases, Université Paris Cité, Paris, France
Martin Petřek PhD
Professor of Pathophysiology, Olomouc University Hospital, Olomouc, Czech Republic
Antje Prasse MD PhD
Professor of Pulmonology, Basel University Hospital, Basel, Switzerland
Paolo Spagnolo MD PhD
Professor of Respiratory Medicine
Padua University Hospital, Padua, Italy
“The Board of Directors of Eurosarcoidosis is pleased to welcome seven eminent and dedicated scientists with deep knowledge of the state of global sarcoidosis research. We have asked them to focus on the design of a draft European Sarcoidosis Research Agenda, which will be circulated for discussion among the medical and scientific communities,” mr Jules Prast, Eurosarcoidosis chairman, stated. “Their support for this initiative will make a world of difference to engage donors and other stakeholders for the Foundation’s ambition to create a European fund for sarcoidosis research”, he continued.
Sarcoidosis or Besnier Boeck disease is a rare and disabling chronic inflammatory disorder with no known cause and no cure. Nodules of inflammatory cells, called granulomas, may interfere with the proper functioning of any organ or tissue in the human body. Fatigue is a hallmark of the disease, which may continue even after inflammatory activity itself has abated. Mortality, mostly due to pulmonary and cardiac complications, ranges between six and eight per cent.
—
Media inquiries:
Eurosarcoidosis
info@eurosarcoidosis.org
+31 34 8 890 890
More Eurosarcoidosis news:
20 February 2024
Eurosarcoidosis voted in as member of EU sarcoidosis platform